The book discusses the recent progress in understanding the therapeutic targets for gallbladder cancer to provide opportunities for research and for developing innovative strategies that may enhance the benefit of conventional chemotherapy. The book focuses on identifying candidate molecules and the overall status of the targeted therapies available for gallbladder cancer, as there is an urgent need to discover new molecular targets that can guide the emergence of new treatment strategies to improve patient outcomes and act as biomarkers for the early detection of diseases. Recently, new treatment therapeutics targets for gallbladder cancer patients have been identified and the field is evolving rapidly. The book is relevant for the clinical researcher, surgeon, scientist and academician.

Gallbladder Cancer: Current treatment options and therapeutics -- Surgical Management of Gallbladder Cancer Patients -- Conventional therapy in Gallbladder Cancer -- Adjuvant Therapy following Surgical Treatment of Gallbladder Cancer -- Incidental gallbladder cancer: the role of routine versus selective histopathological examination of gallbladder specimens after cholecystectomy -- Minimally Invasive Surgery for Management of Gallbladder Cancer -- Thickwalled Gallbladder: Differential diagnosis and surgical approach to a thickened gallbladder -- Management of incidentally detected gallbladder cancer after cholecystectomy -- Adjuvant treatment in radically resected gallbladder cancer -- A look at emerging therapeutic targets for gallbladder cancer: a multi-omics approach -- MicroRNA and their role in Carcinoma Gallbladder -- Gallbladder cancer: Epigenetic landscape, Targeted therapy and Prospect of Epitherapy -- Targeted treatment of Gallbladder cancer -- Molecular pathways in Gallbladder cancer as potential therapeutic target -- Targeted Therapy: Molecular Pathology and Targets of Gallbladder Cancer -- Targeted Therapies in Gallbladder Cancer: Current Status and Future Perspectives -- Integrative omics - the roadmap for gallbladder biomarkers identification -- Anti-EGFR Therapy in Gall Bladder Cancer.